Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study

Mahmood Mahajna, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, Ilan Matok, Haoming Zhang · 2023

Read Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study by Mahmood Mahajna, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, Ilan Matok, Haoming Zhang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10740827.txt.

Description

Mahajna and co-authors test whether a gene based drug test predicts how depressed patients fare on two common antidepressants. Both drugs are broken down by one liver enzyme, CYP2C19, whose inherited variants speed or slow the job. Their 2023 study follows 283 outpatients with test results on file and tracks side effects, adherence, and treatment changes over time.

Patients whose genes implied faster enzyme action tolerated the drugs better, with odds of intolerance falling per step of activity. A grouping analysis split patients into two camps: one with many side effects, poor adherence, and frequent switches, the other smooth on all three. Gene status strongly predicted camp membership. The authors say the test carries real predictive value for these medicines.

Catalog record

CREATORMahmood Mahajna, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, Ilan Matok, Haoming Zhang
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10740827

Browse the full library · About the Tower of Babel